Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center
Articles
Evolving HCC Treatment Landscape: Combination Therapy
Peter R. Galle, MD, PhD, Mainz University Medical Center;Pierre Gholam, MD, UH Westlake Health Center;Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center;Richard S. Finn, MD, Geffen School of Medicine;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
October 30th 2020Read More
Developing Trial Regimens for Chinese Populations
Peter R. Galle, MD, PhD, Mainz University Medical Center;Pierre Gholam, MD, UH Westlake Health Center;Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center;Richard S. Finn, MD, Geffen School of Medicine;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
October 30th 2020Read More
High AFP as Deciding Factor for Treatment
Peter R. Galle, MD, PhD, Mainz University Medical Center;Pierre Gholam, MD, UH Westlake Health Center;Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center;Richard S. Finn, MD, Geffen School of Medicine;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
October 30th 2020Read More
Immunotherapy Monotherapy in Later-Line Setting
Peter R. Galle, MD, PhD, Mainz University Medical Center;Pierre Gholam, MD, UH Westlake Health Center;Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center;Richard S. Finn, MD, Geffen School of Medicine;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
October 30th 2020Read More
Second-Line Options After IMbrave150 Regimen
Peter R. Galle, MD, PhD, Mainz University Medical Center;Pierre Gholam, MD, UH Westlake Health Center;Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center;Richard S. Finn, MD, Geffen School of Medicine;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
October 30th 2020Read More
Promising Ongoing Frontline Trials
Peter R. Galle, MD, PhD, Mainz University Medical Center;Pierre Gholam, MD, UH Westlake Health Center;Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center;Richard S. Finn, MD, Geffen School of Medicine;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
October 30th 2020Read More
Importance of Endoscopy in Newly Diagnosed HCC
Peter R. Galle, MD, PhD, Mainz University Medical Center;Pierre Gholam, MD, UH Westlake Health Center;Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center;Richard S. Finn, MD, Geffen School of Medicine;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
October 30th 2020Read More
NCCN Guidelines: Nivolumab in Frontline Setting
Peter R. Galle, MD, PhD, Mainz University Medical Center;Pierre Gholam, MD, UH Westlake Health Center;Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center;Richard S. Finn, MD, Geffen School of Medicine;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
October 30th 2020Read More
Optimal HCC Frontline Treatments
Peter R. Galle, MD, PhD, Mainz University Medical Center;Pierre Gholam, MD, UH Westlake Health Center;Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center;Richard S. Finn, MD, Geffen School of Medicine;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
October 30th 2020Read More
The TACE Approach for Intermediate-Stage Disease
Peter R. Galle, MD, PhD, Mainz University Medical Center;Pierre Gholam, MD, UH Westlake Health Center;Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center;Richard S. Finn, MD, Geffen School of Medicine;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
October 30th 2020Read More
Screening Vs Diagnosis: Assessing Liver Function
Peter R. Galle, MD, PhD, Mainz University Medical Center;Pierre Gholam, MD, UH Westlake Health Center;Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center;Richard S. Finn, MD, Geffen School of Medicine;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
October 30th 2020Read More
The Complexity of HCC Multidisciplinary Management
Peter R. Galle, MD, PhD, Mainz University Medical Center;Pierre Gholam, MD, UH Westlake Health Center;Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center;Richard S. Finn, MD, Geffen School of Medicine;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
October 30th 2020Read More
Latest Updated Articles
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
